Form 4: Cartesian Therapeutics CAO Granted Stock Options

Cartesian Therapeutics' Chief Accounting Officer, June Ann Seymour, was granted 50,000 employee stock options with an exercise price of $8.85.

Summary

• June Ann Seymour, Chief Accounting Officer of Cartesian Therapeutics, Inc. (RNAC), acquired 50,000 employee stock options.
• The transaction date for the option grant was October 27, 2025.
• Each option has an exercise price of $8.85.
• The options will vest as to 25% on October 27, 2026.
• The remaining shares underlying the options will vest in three equal annual installments thereafter, leading to full vesting on October 27, 2029.
• The expiration date for these stock options is October 27, 2035.
• Following this transaction, June Ann Seymour beneficially owns 50,000 derivative securities (employee stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally viewed as a neutral to slightly positive event, as it aligns management incentives with shareholder interests, without directly impacting current financial performance or indicating operational changes.

Positives

• The grant of stock options to a key executive aligns management's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule encourages executive retention and sustained commitment to the company's success over several years.

Future Outlook

The filing details a vesting schedule for employee stock options, indicating a long-term incentive structure for the Chief Accounting Officer, with full vesting expected by October 27, 2029.

Industry Context

The grant of stock options is a standard practice in the biotechnology and pharmaceutical industry, commonly used to attract, retain, and incentivize key executives by linking their compensation to the company's stock performance.

Stakeholder Impact

• Shareholders: The grant of options aims to align the Chief Accounting Officer's financial interests with shareholder value creation over the long term.
• Employees: This reflects the company's compensation strategy for its executive team, potentially influencing overall employee incentive programs.

Next Steps

• The stock options will begin vesting on October 27, 2026, with subsequent annual installments until fully vested on October 27, 2029.

Key Dates

Keywords

Cartesian Therapeutics, RNAC, Stock Options, Executive Compensation, Insider Transaction, Form 4, Chief Accounting Officer, Equity Grant